mHealth application for improving treatment outcomes for patients with multidrug-resistant tuberculosis in Vietnam: an economic evaluation protocol for the V-SMART trial

BMJ Open - Tập 13 Số 12 - Trang e076778 - 2023
Qinglu Cheng1,2, Tho Dang3, Thu-Anh Nguyen3,4,5, Kavindhran Velen4,5, Viet Nhung Nguyen6, Binh Hoa Nguyen6, Dinh Hoa Vu7, Chuong Huynh Long3, Thu Thuong Do6, Truong-Minh Vu8, Guy B Marks3,9,2, Manisha Yapa4,5, Gregory J Fox3,4,5, Virginia Wiseman1,2,10,11
1Kirby Institute
2University of New South Wales
3Woolcock Institute of Medical Research
4Faculty of Medicine and Health
5The University of Sydney
6Vietnam National Tuberculosis Control Program
8Ho Chi Minh city Institute for Development Studies
9School of Clinical Medicine
10Department of Global Health and Development
11London School of Hygiene & Tropical Medicine

Tóm tắt

Introduction The Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART) trial is a randomised controlled trial of using mobile health (mHealth) technologies to improve adherence to medications and management of adverse events (AEs) in people with multidrug-resistant tuberculosis (MDR-TB) undergoing treatment in Vietnam. This economic evaluation seeks to quantify the cost-effectiveness of this mHealth intervention from a healthcare provider and societal perspective. Methods and analysis The V-SMART trial will recruit 902 patients treated for MDR-TB across seven participating provinces in Vietnam. Participants in both intervention and control groups will receive standard community-based therapy for MDR-TB. Participants in the intervention group will also have a purpose-designed App installed on their smartphones to report AEs to health workers and to facilitate timely management of AEs. This economic evaluation will compare the costs and health outcomes between the intervention group (mHealth) and the control group (standard of care). Costs associated with delivering the intervention and health service utilisation will be recorded, as well as patient out-of-pocket costs. The health-related quality of life (HRQoL) of study participants will be captured using the 36-Item Short Form Survey (SF-36) questionnaire and used to calculate quality-adjusted life-years (QALYs). Incremental cost-effectiveness ratios (ICERs) will be based on the primary outcome (proportion of patients with treatment success after 24 months) and QALYs gained. Sensitivity analysis will be conducted to test the robustness of the ICERs. A budget impact analysis will be conducted from a payer perspective to provide an estimate of the total budget required to scale-up delivery of the intervention. Ethics and dissemination Ethical approval for the study was granted by the University of Sydney Human Research Ethics Committee (2019/676), the Scientific Committee of the Ministry of Science and Technology, Vietnam (08/QD-HDQL-NAFOSTED) and the Institutional Review Board of the National Lung Hospital, Vietnam (13/19/CT-HDDD). Study findings will be published in peer-reviewed journals and conference proceedings. Trial registration number ACTRN12620000681954.

Từ khóa


Tài liệu tham khảo

citation_title=Tuberculosis fact sheet;citation_year=2018

citation_title=Global tuberculosis report 2022;citation_year=2022

citation_title=Tuberculosis profile: Viet Nam. TB country, regional and global profiles;citation_year=2022

citation_title=Report of Vietnam National Tuberculosis Programme, N.T. Program;citation_year=2021

citation_journal_title=Int J Tuberc Lung Dis;citation_author=RH. Berhanu;citation_author=K. Schnippel;citation_author=R. Kularatne;citation_title=Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia;citation_pages=358-62;citation_volume=22;citation_year=2018;citation_pmid=http://www.n

citation_journal_title=Infect Dis Poverty;citation_title=Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia’s implementation of universal health coverage;citation_volume=7;citation_year=2018

citation_journal_title=PLoS Med;citation_title=Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study;citation_volume=11;citation_year=2014

citation_title=WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update;citation_year=2022

citation_journal_title=Indian J Med Res;citation_author=S. Sharma;citation_author=K. Dheda;citation_title=World health organization, WHO consolidated guidelines on drug-resistant tuberculosis treatment;citation_pages=309;citation_volume=149;citation_year=2019;citation_pmid=http://www.n

citation_journal_title=Am J Ther;citation_author=S. Wu;citation_author=Y. Zhang;citation_author=F. Sun;citation_title=Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis;citation_pages=e521-30;citation_volume=23;citation_year=2016;citation_pmid=24284652;citation_doi=10.1097/01.mjt.0000433951.09030.5a

citation_journal_title=Lancet Respir Med;citation_author=Z. Lan;citation_author=N. Ahmad;citation_author=P. Baghaei;citation_title=Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis;citation_pages=383-94;citation_volume=8;citation_year=2020

citation_journal_title=Med Sci Monit;citation_author=Y. Zhang;citation_author=S. Wu;citation_author=Y. Xia;citation_title=Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study;citation_pages=2348-56;citation_volume=23;citation_year=2017

citation_journal_title=BMC Infect Dis;citation_title=Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda;citation_volume=23;citation_year=2023

citation_journal_title=PLoS One;citation_title=Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter Injectable based regimen in West Java Indonesia;citation_volume=17;citation_year=2022

citation_journal_title=Infect Drug Resist;citation_author=T. Belachew;citation_author=S. Yaheya;citation_author=N. Tilahun;citation_title=Multidrug-resistant tuberculosis treatment outcome and associated factors at the University of Gondar comprehensive specialized hospital: a ten-year retrospective study;citation_pages=2891-9;citation_volume=15;citation_year=2022

citation_journal_title=BMC Infect Dis;citation_title=Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh city: a retrospective study;citation_volume=20;citation_year=2020

citation_journal_title=BMJ Open;citation_title=Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti region, Ghana: a retrospective, cross-sectional study;citation_volume=12;citation_year=2022

citation_journal_title=Clin Microbiol Infect;citation_author=A. Javaid;citation_author=I. Ullah;citation_author=H. Masud;citation_title=Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study;citation_pages=612-7;citation_volume=24;citation_year=2018;citation_pmid=http://www.n

citation_journal_title=Infect Drug Resist;citation_author=W. Xing;citation_author=R. Zhang;citation_author=W. Jiang;citation_title=Adherence to multidrug resistant tuberculosis treatment and case management in Chongqing, China - a mixed method research study;citation_pages=999-1012;citation_volume=14;citation_year=2021

citation_journal_title=Afr Health Sci;citation_author=C. Batte;citation_author=MS. Namusobya;citation_author=R. Kirabo;citation_title=Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago national referral hospital, Kampala, Uganda;citation_pages=238-47;citation_volume=21;citation_year=2021

citation_journal_title=BMC Pulm Med;citation_title=Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects;citation_volume=21;citation_year=2021

citation_title=WHO Global Observatory for eHealth, mHealth: new horizons for health through mobile technologies: second global survey on eHealth;citation_year=2011

citation_journal_title=Eur Heart J Qual Care Clin Outcomes;citation_author=Y. Gandapur;citation_author=S. Kianoush;citation_author=HM. Kelli;citation_title=The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review;citation_pages=237-44;citation_volume=2;citation_year=2016

citation_journal_title=Int J Clin Pract;citation_author=H. Anglada-Martinez;citation_author=G. Riu-Viladoms;citation_author=M. Martin-Conde;citation_title=Does mHealth increase adherence to medication? Results of a systematic review;citation_pages=9-32;citation_volume=69;citation_year=2015;citation_pmid=25472682;citation_doi=10.1111/ijcp.12582

citation_journal_title=J Med Internet Res;citation_title=Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review;citation_volume=17;citation_year=2015

citation_journal_title=Curr Hypertens Rep;citation_title=Effectiveness of mHealth interventions in improving medication adherence among people with hypertension: a systematic review;citation_volume=20;citation_year=2018

citation_journal_title=Eur Respir J;citation_title=Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review;citation_volume=53;citation_year=2019

citation_journal_title=BMC Med;citation_title=Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation;citation_volume=17;citation_year=2019

citation_journal_title=Value Health;citation_author=SD. Sullivan;citation_author=JA. Mauskopf;citation_author=F. Augustovski;citation_title=Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force;citation_pages=5-14;citation_volume=17;citation_year=2014;citation_pmid=24438712;citation_doi=10.1016/j.jval.2013.08.2291

citation_journal_title=Environ Health Prev Med;citation_title=A review of Vietnam’s healthcare reform through the direction of healthcare activities (DOHA);citation_volume=22;citation_year=2017

citation_journal_title=BMJ Open;citation_title=Harnessing new mHealth technologies to strengthen the management of multidrug-resistant tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial;citation_volume=12;citation_year=2022

citation_journal_title=Glob Health Action;citation_title=Step-by-step guideline for disease-specific costing studies in Low- and middle-income countries: a mixed methodology;citation_volume=7;citation_year=2014

citation_journal_title=Pharmacoeconomics;citation_author=M. Krol;citation_author=W. Brouwer;citation_author=F. Rutten;citation_title=Productivity costs in economic evaluations: past, present, future;citation_pages=537-49;citation_volume=31;citation_year=2013;citation_pmid=23620213;citation_doi=10.1007/s40273-013-0056-3

citation_journal_title=Asia Pacific Journal of Public Health;citation_journal_abbrev=Asia Pac J Public Health;citation_author=RE. Watkins;citation_author=AJ. Plant;citation_author=D. Sang;citation_title=Development of a Vietnamese Version of the Short Form-36 Health Survey;citation_pages=118-123;citation_volume=12;citation_year=2000;citation_issue=2;citation_pmid=11841039;citation_doi=10.1177/101053950001200211

citation_journal_title=J Aging Health;citation_author=Q. Ngo-Metzger;citation_author=DH. Sorkin;citation_author=CM. Mangione;citation_title=Evaluating the SF-36 health survey (version 2) in older Vietnamese Americans;citation_volume=20;citation_year=2008;citation_pmid=18381886;citation_doi=10.1177/0898264308315855

citation_journal_title=Pharmacoeconomics;citation_author=R. Faria;citation_author=M. Gomes;citation_author=D. Epstein;citation_title=A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials;citation_pages=1157-70;citation_volume=32;citation_year=2014;citation_pmid=25069632;citation_doi=10.1007/s40273-014-0193-3

citation_title=Making choices in health: WHO guide to cost-effectiveness analysis;citation_year=2003

citation_journal_title=Value Health;citation_author=OT. Due;citation_author=A. Thakkinstian;citation_author=M. Thavorncharoensap;citation_title=Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam;citation_pages=1180-90;citation_volume=23;citation_year=2020

citation_journal_title=AIDS Behav;citation_author=NA. Blackburn;citation_author=VF. Go;citation_author=Q. Bui;citation_title=The cost-effectiveness of adapting and implementing a brief intervention to target frequent alcohol use among persons with HIV in Vietnam;citation_pages=2108-19;citation_volume=25;citation_year=2021

citation_journal_title=Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research;citation_journal_abbrev=Value Health;citation_author=JA. Mauskopf;citation_author=SD. Sullivan;citation_author=L. Annemans;citation_title=Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.;citation_pages=336-347;citation_volume=10;citation_year=2007;citation_issue=5;citation_pmid=17888098;citation_doi=10.1111/j.1524-4733.2007.00187.x

citation_journal_title=Value Health;citation_author=SD. Sullivan;citation_author=JA. Mauskopf;citation_author=F. Augustovski;citation_title=Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force;citation_pages=5-14;citation_volume=17;citation_year=2014;citation_pmid=24438712;citation_doi=10.1016/j.jval.2013.08.2291

citation_journal_title=BMC Infect Dis;citation_title=Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study;citation_volume=22;citation_year=2022

citation_journal_title=JMIR Mhealth Uhealth;citation_title=Long-term effectiveness of a Smartphone App for improving healthy lifestyles in general population in primary care: randomized controlled trial (evident II study);citation_volume=6;citation_year=2018

citation_journal_title=J Med Internet Res;citation_title=The association between logging steps using a Website, App, or Fitbit and engaging with the 10,000 steps physical activity program: observational study;citation_volume=23;citation_year=2021

Thông tin
Thông tin xuất bản

BMJ Open

Tập 13 Số 12

e076778

Thông tin tác giả